Remi Bader's Weight Loss Doesn't Make Her Less “Relatable.” Fat People Aren't Here For Your Comfort
"Following a fat woman because she’s ‘relatable’ traps her into being your proverbial pillow, or at worst your punching bag." ...
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.
Where Will Hims & Hers Stock Be in Five Years? Here’s What This Top Investor Expects
Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...
The Average Weight for American Women
The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are ...
Facing high costs and drug shortages, they turned to compounded weight loss drugs online. An FDA ban might end that.
Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...
Here’s why Hims & Hers stock price has crashed: buy the dip?
Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
STAT8d
Pharmalittle: We’re reading about copycat weight loss drugs, ADHD prescriptions spiking, and more
The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...
Barron's8d
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...